|Bid||7.41 x 800|
|Ask||7.70 x 4900|
|Day's range||7.16 - 7.65|
|52-week range||5.77 - 17.99|
|PE ratio (TTM)||N/A|
|Earnings date||6 Nov 2017 - 10 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.31|
Lidoderm, Opana ER, and Percocet are Endo's top pain management drugs, contributing revenues of ~$88 million, ~$159 million and ~$139 million, respectively.
In 2016 and 2015, Endo's US Generic segment contributed 64% and 51% of total revenues, respectively. The US Branded segment contributed 29% and 39.
Of the 21 analysts covering Endo in November 2017, six recommend a “buy” for the stock, while 14 recommend a "hold," and one recommends a "sell."
A federal jury in Chicago said on Thursday that Endo International (NasdaqGS: ENDP - news) 's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim. The verdict was a victory for the drugmaker in its first trial over allegations it defectively designed Testim, a skin gel, and negligently misrepresented its risks. Matthew Maletta, Endo's chief legal officer, said in a statement that Testim was safe and Endo would continue to vigorously defend against similar claims.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Endo International, Plc. .
On a per-share basis, the Dublin-based company said it had a loss of 43 cents. Earnings, adjusted for one-time gains and costs, were 91 cents per share. The results topped Wall Street expectations. The ...
Kentucky joins the roster of states and communities suing opioid makers, this time focused on Endo and its withdrawn painkiller Opana ER.
Endo International (ENDP) is surging Monday morning, after forecasting higher-than-expected third-quarter earnings. Endo pre-announced third quarter earnings per share of 85 cents, 19 cents above consensus, and while it maintained its 2017 EBITDA and EPS guidance, it now expects adjusted EBITDA from continuing operations and adjusted diluted EPS from continuing operations to be at the upper end of its 2017 financial guidance ranges. The shares, which have tumbled nearly 62% year to date, jumped on the news, but Cantor Fitzgerald's Louise Chen and her team warn investors shouldn't get too excited.
The generic pharmaceutical leader is suing the Food and Drug Administration -- and it might be right. Then again, it might not matter.
The deal comes at a time when speedy approvals of generics by U.S. regulators have ratcheted up competition in the sector, mounting pressure on smaller drugmakers such as Impax, which has a market cap of about $1.48 billion (£1.1 billion). Adding to the woes of generics makers, U.S. retail pharmacies including Wal-Mart Stores Inc (WMT.N) and Walgreens Boots Alliance Inc (WBA.O) are wielding more leverage when buying such drugs, leading to continued price erosion.
Omeros Corporation shares surged as much as 10% in morning trade Thursday, before paring some gains, after the company announced a settlement with Endo International PLC's Par Pharmaceutical Inc. that ...
BMO Capital Markets' Gary Nachman and his team recently hosted an event with executives from Valeant Pharmaceuticals (VRX), Impax Laboratories (IPXL) and Endo International (ENDP), as they try to navigate a "challenging time in specialty pharma." Nachman writes that all three companies have a high amount of leverage, but they're taking different approaches: While Valeant and Endo are taking a more long-term approach of addressing concerns about their debt by executing their main businesses, Impax appears to be planning a "creative transaction" in the near-term that Nachman writes could "potentially transform the company," while also delevering its balance sheet.
Stocks look set for a lower open today as Trump's tax plan continues to dominate the news. S&P 500 futures have declined 0.2%, while Dow Jones Industrial Average futures have fallen 0.2%. Nasdaq Composite ...
Indivior's U.S. subsidiary, together with Monosol Rx, has settled a patent dispute with U.S. drugmaker Mylan related to generic versions of its opioid addiction treatment Suboxone, which generates 80 percent ...
Indivior (Frankfurt: 2IVA.F - news) 's U.S. subsidiary has filed lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of the drugmaker's revenue. The patent lawsuits were filed against Dr. Reddy's , Allergan Plc (Frankfurt: A1W5NE - news) 's Actavis Laboratories, Endo International's Par Pharmaceutical, Alvogen Pharma US, Teva Pharmaceutical Industries and Mylan NV.
Indivior said on Friday its U.S. subsidiary has filed patent lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of Indivior's ...
The S&P 500 fell on Tuesday after edging up to an intra-day record high for the second straight session, while Apple became the first U.S. company to close with a market capitalization above $800 billion. Better-than-expected quarterly earnings from U.S. companies and Emmanuel Macron's victory in the French presidential election on Sunday have given investors confidence, but valuations for U.s. stocks are already higher than average. The hope that U.S. President Donald Trump will cut corporate and personal taxes remained in focus for investors.
The S&P 500 slipped marginally on Tuesday after edging up to an intra-day record high for the second straight session, with a rise in Marriott International (Frankfurt: 913070 - news) and other consumer discretionary shares offsetting falling energy shares. Better-than-expected quarterly earnings from U.S. companies and Emmanuel Macron's victory in the French presidential election on Sunday have given investors confidence, but valuations for U.s. stocks are already higher than average.